Assessment of the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred to as AS MDI) Compared to Proventil as an Active Control in Subjects With Asthma

This is a randomized, cumulative dose, open-label, 2-period crossover, multi-center study to
assess the safety, efficacy, PK, and extrapulmonary pharmacodynamics (PD) of cumulative doses
of Albuterol Sulfate Pressurized Inhalation Suspension (hereafter referred to as AS MDI)
compared to cumulative doses of Proventil® hydrofluoroalkane (HFA; hereafter referred to as
Proventil) as an active control in subjects with mild to moderate asthma.

Inclusion Criteria:

- Have stable (for 6 months) physician-diagnosed asthma with historical documentation of
the diagnosis

- Must be receiving 1 of the following required inhaled asthma therapies listed below
for at least the last 30 days; Only SABA, which is used as needed for rescue, or Low
to medium doses of ICS (alone or in combination with LABA), used regularly as
maintenance asthma therapy

- Demonstrate acceptable spirometry performance (ie, meet American Thoracic Society
[ATS]/European Respiratory Society [ERS] acceptability/repeatability criteria

- Pre-bronchodilator FEV1 of ≥50 to <80% predicted normal value after withholding SABA
≥6 hours

- Confirmed FEV1 reversibility to Ventolin, defined as a post-Ventolin increase in FEV1
of ≥15%

- Only 2 reversibility testing attempts are allowed

Exclusion Criteria:

- Chronic obstructive pulmonary disease or other significant lung disease (eg, chronic
bronchitis, emphysema, bronchiectasis with the need of treatment, cystic fibrosis, or
bronchopulmonary dysplasia)

- Oral corticosteroid use (any dose) within 6 weeks

- Received any marketed (eg, omalizumab, mepolizumab, reslizumab) or investigational
biologic within 3 months or 5 half-lives, whichever is longer, or any other medication
specifically prohibited by the protocol

- Current smokers, former smokers with >10 pack-years history, or former smokers who
stopped smoking <6 months (including all forms of tobacco, e-cigarettes [vaping], and
marijuana)

- Life-threatening asthma as defined as any history of significant asthma episode(s)
requiring intubation associated with hypercapnia, respiratory arrest, hypoxic
seizures, or asthma-related syncopal episode(s)

- Historical or current evidence of a clinically significant disease

- Cancer not in complete remission for at least 5 years

- Hospitalized for psychiatric disorder or attempted suicide within 1 year

- Unable to abstain from protocol-defined prohibited medications during the study